Genmab A/S (NASDAQ:GMAB - Free Report) - Equities researchers at HC Wainwright upped their FY2025 earnings per share (EPS) estimates for shares of Genmab A/S in a research note issued to investors on Thursday, April 24th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of $1.58 per share for the year, up from their previous forecast of $1.48. HC Wainwright currently has a "Buy" rating and a $37.00 target price on the stock. The consensus estimate for Genmab A/S's current full-year earnings is $1.45 per share. HC Wainwright also issued estimates for Genmab A/S's Q4 2025 earnings at $0.47 EPS, Q1 2026 earnings at $0.29 EPS, Q2 2026 earnings at $0.53 EPS, Q3 2026 earnings at $0.51 EPS and Q4 2026 earnings at $0.52 EPS.
A number of other research analysts also recently issued reports on GMAB. Leerink Partners upgraded Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 price target on the stock in a research note on Thursday, February 13th. William Blair raised shares of Genmab A/S from a "market perform" rating to an "outperform" rating in a report on Tuesday, March 11th. BNP Paribas upgraded shares of Genmab A/S from a "strong sell" rating to a "hold" rating in a research note on Tuesday, February 11th. Leerink Partnrs upgraded shares of Genmab A/S from a "hold" rating to a "strong-buy" rating in a research note on Thursday, February 13th. Finally, Truist Financial lowered their price target on Genmab A/S from $50.00 to $45.00 and set a "buy" rating on the stock in a report on Tuesday, March 11th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Genmab A/S presently has a consensus rating of "Moderate Buy" and an average target price of $39.17.
Check Out Our Latest Report on Genmab A/S
Genmab A/S Price Performance
Shares of GMAB traded up $0.36 during mid-day trading on Monday, reaching $21.15. The company's stock had a trading volume of 1,354,443 shares, compared to its average volume of 1,054,684. The company's 50 day moving average is $20.41 and its 200 day moving average is $21.00. The stock has a market cap of $13.56 billion, a PE ratio of 12.16, a price-to-earnings-growth ratio of 2.65 and a beta of 1.07. Genmab A/S has a 12-month low of $17.24 and a 12-month high of $30.41.
Genmab A/S (NASDAQ:GMAB - Get Free Report) last released its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 EPS for the quarter, topping the consensus estimate of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%.
Institutional Investors Weigh In On Genmab A/S
Several hedge funds and other institutional investors have recently bought and sold shares of GMAB. EverSource Wealth Advisors LLC lifted its position in shares of Genmab A/S by 295.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company's stock valued at $26,000 after acquiring an additional 939 shares during the last quarter. Lindbrook Capital LLC increased its stake in Genmab A/S by 105.4% in the 4th quarter. Lindbrook Capital LLC now owns 1,851 shares of the company's stock worth $39,000 after purchasing an additional 950 shares in the last quarter. GAMMA Investing LLC raised its holdings in Genmab A/S by 96.6% during the 4th quarter. GAMMA Investing LLC now owns 2,139 shares of the company's stock worth $45,000 after buying an additional 1,051 shares during the period. Barclays PLC lifted its stake in Genmab A/S by 1,072.8% during the fourth quarter. Barclays PLC now owns 2,498 shares of the company's stock valued at $52,000 after buying an additional 2,285 shares in the last quarter. Finally, Cromwell Holdings LLC boosted its holdings in shares of Genmab A/S by 656.8% in the fourth quarter. Cromwell Holdings LLC now owns 2,876 shares of the company's stock worth $60,000 after buying an additional 2,496 shares during the period. 7.07% of the stock is currently owned by institutional investors.
About Genmab A/S
(
Get Free Report)
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Further Reading
Before you consider Genmab A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.
While Genmab A/S currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
